JAK Inhibitor denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Step Therapy for JAK Inhibitors — and How to Appeal a Step-Therapy Denial

Step therapy (also called "fail-first" requirements) is one of the most common barriers to JAK inhibitors at Cigna. The plan requires documented evidence that the patient has tried — and not responded adequately to — one or more earlier-line medications before it will authorize a JAK inhibitor. When that documentation is missing or deemed insufficient, the claim is denied. Step-therapy denials are appealable, and many are successfully overturned with the right documentation.

## Why This Denial Happens

Cigna's step-therapy protocols for JAK inhibitors typically require prior trials of agents such as conventional disease-modifying drugs or, for some indications, biologic agents, before a JAK inhibitor will be covered. A denial may issue because the submitted records did not explicitly document prior therapy outcomes, because the step was completed with a different prescriber whose records were not submitted, or because a step-therapy exception was not requested at the PA stage.

## Your Appeal Rights

• Step-Therapy Exception Laws: many states have enacted step-therapy override laws requiring insurers to grant exceptions when step therapy is clinically contraindicated, when the required agent was previously tried, or when the step-therapy requirement would cause serious harm. Check whether your state's law applies to your plan type.
• ERISA §503: employer-sponsored self-funded plans are generally exempt from state step-therapy laws, but still owe you a full-and-fair review with access to the denial criteria.
• ACA §2719 External Review: available after exhausting internal appeals. The window is approximately four months from final adverse determination — verify on your denial letter. Expedited review is available for urgent cases.

## Concrete Appeal Process

1. Obtain Cigna's published step-therapy protocol for the specific JAK inhibitor and indication — you are entitled to this document. 2. Identify which step(s) Cigna claims were not satisfied. 3. Gather complete records for every prior therapy trial, including prescribing records from any prior provider. 4. If a step was clinically inappropriate (contraindicated, previously failed, or would cause harm), document that specifically. 5. File the internal appeal; request step-therapy exception explicitly. 6. If denied, escalate to external review.

## Documentation to Gather

• Prior-therapy records: for each required step, the prescribing notes, dates of treatment, doses as recorded in the chart, and documented reason for stopping (inadequate response, adverse effect, contraindication).
• Treating physician letter: explicitly addressing each step in Cigna's protocol and explaining why the patient has either completed it or is exempt.
• FDA prescribing label: for the specific JAK inhibitor, confirming the approved indication and any statements relevant to prior-therapy requirements.
• Relevant specialist-society guideline: for example, the applicable ACR, AAD, or AGA guideline for your condition, which may support JAK inhibitor use at this stage of treatment.

## Criteria-Mapping Structure

List each step in Cigna's protocol. For each, provide the chart evidence of completion or the clinical reason for exemption. Attach the underlying records as exhibits. This structure directly mirrors the protocol and makes it easy for the reviewer — and any external reviewer — to verify that each step has been addressed.